Oculis Announces an Oversubscribed US$57 million Series C Financing

Oculis Announces an Oversubscribed US$57 million Series C Financing

04.5.2021 – Oculis S.A., a late-stage biopharmaceutical company based at Innovation Park, focused on developing transformative ophthalmic treatments to improve the sight and lives of patients, today announced that it has closed an oversubscribed US$57 million Series C financing. The round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund, Silfurberg, as well as other existing investors. This excellent syndication further broadens Oculis’ strong shareholder base of leading life sciences investors from the US, China and Europe.

Read more